You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

ONDANSETRON HYDROCHLORIDE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for ondansetron hydrochloride and what is the scope of freedom to operate?

Ondansetron hydrochloride is the generic ingredient in six branded drugs marketed by Accord Hlthcare, Am Regent, Apotex Inc, Avet Lifesciences, Baxter Hlthcare Corp, Chartwell Molecular, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Hikma Farmaceutica, Hospira, Lannett Co Inc, Luitpold, Pliva Hrvatska Doo, Qilu Pharm Hainan, Rising, Sagent Pharms, Sandoz, Steriscience Speclts, Sun Pharm Inds (in), Teva, Wockhardt, Sun Pharm Inds Ltd, Taro Pharms Ireland, Glaxosmithkline, Amneal Pharms, Aurobindo Pharma, Pharm Assoc, Taro, Apotex, Chartwell Molecules, Chartwell Rx, Dr Reddys Labs Ltd, Glenmark Pharms Ltd, Hikma Intl Pharms, Ipca Labs Ltd, and Natco Pharma Ltd, and is included in seventy-two NDAs. Additional information is available in the individual branded drug profile pages.

There are sixteen drug master file entries for ondansetron hydrochloride. Sixty-six suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for ONDANSETRON HYDROCHLORIDE
US Patents:0
Tradenames:6
Applicants:38
NDAs:72
Drug Master File Entries: 16
Finished Product Suppliers / Packagers: 66
Raw Ingredient (Bulk) Api Vendors: 81
Clinical Trials: 615
Patent Applications: 2,135
What excipients (inactive ingredients) are in ONDANSETRON HYDROCHLORIDE?ONDANSETRON HYDROCHLORIDE excipients list
DailyMed Link:ONDANSETRON HYDROCHLORIDE at DailyMed
Recent Clinical Trials for ONDANSETRON HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Yongtao SunPhase 4
King Saud Medical CityPhase 3
Ain Shams UniversityN/A

See all ONDANSETRON HYDROCHLORIDE clinical trials

Generic filers with tentative approvals for ONDANSETRON HYDROCHLORIDE
Applicant Application No. Strength Dosage Form
⤷  Sign Up⤷  Sign UpEQ 2MG BASE/MLINJECTABLE;INJECTION
⤷  Sign Up⤷  Sign UpEQ 2MG BASE/MLINJECTABLE;INJECTION

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for ONDANSETRON HYDROCHLORIDE
Paragraph IV (Patent) Challenges for ONDANSETRON HYDROCHLORIDE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
ZOFRAN Oral Solution ondansetron hydrochloride 4 mg/5 mL 020605 1 2004-12-20

US Patents and Regulatory Information for ONDANSETRON HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius Kabi Usa ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE ondansetron hydrochloride INJECTABLE;INJECTION 202253-001 Jul 19, 2013 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Dr Reddys Labs Ltd ONDANSETRON HYDROCHLORIDE ondansetron hydrochloride TABLET;ORAL 076183-003 Dec 26, 2006 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sandoz ZOFRAN ondansetron hydrochloride SOLUTION;ORAL 020605-001 Jan 24, 1997 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Ipca Labs Ltd ONDANSETRON HYDROCHLORIDE ondansetron hydrochloride TABLET;ORAL 203761-002 Jan 23, 2014 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Wockhardt ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE ondansetron hydrochloride INJECTABLE;INJECTION 077716-001 Dec 26, 2006 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Steriscience Speclts ONDANSETRON HYDROCHLORIDE ondansetron hydrochloride INJECTABLE;INJECTION 078257-001 Apr 23, 2008 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Aurobindo Pharma ONDANSETRON HYDROCHLORIDE ondansetron hydrochloride TABLET;ORAL 078539-003 Jul 31, 2007 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ONDANSETRON HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sandoz ZOFRAN ondansetron hydrochloride SOLUTION;ORAL 020605-001 Jan 24, 1997 ⤷  Sign Up ⤷  Sign Up
Sandoz ZOFRAN ondansetron hydrochloride TABLET;ORAL 020103-002 Dec 31, 1992 ⤷  Sign Up ⤷  Sign Up
Sandoz ZOFRAN ondansetron hydrochloride TABLET;ORAL 020103-002 Dec 31, 1992 ⤷  Sign Up ⤷  Sign Up
Glaxosmithkline ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER ondansetron hydrochloride INJECTABLE;INJECTION 020403-001 Jan 31, 1995 ⤷  Sign Up ⤷  Sign Up
Sandoz ZOFRAN PRESERVATIVE FREE ondansetron hydrochloride INJECTABLE;INJECTION 020007-003 Dec 10, 1993 ⤷  Sign Up ⤷  Sign Up
Sandoz ZOFRAN ondansetron hydrochloride TABLET;ORAL 020103-003 Aug 27, 1999 ⤷  Sign Up ⤷  Sign Up
Sandoz ZOFRAN ondansetron hydrochloride TABLET;ORAL 020103-003 Aug 27, 1999 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.